HealthcareServices

Geographic Atrophy Market Forecast 2026–2035: Data Trends and Industry Insights

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the geographic atrophy market from 2026–2035 with trusted insights from The Business Research Company

How much is the Geographic Atrophy Market valued at in 2026, and what valuation is forecast for 2030?

The geographic atrophy market has shown rapid expansion over recent years. It is projected to increase from $2.11 billion in 2025 to $2.4 billion in 2026, representing a compound annual growth rate (CAGR) of 13.3%. The historic growth can be linked to several factors, including an expanding aging population, the common occurrence of age-related macular degeneration, advancements in retinal imaging, initial ophthalmic drug development efforts, and clinical research funding.

The geographic atrophy market is projected to experience substantial expansion in the coming years, reaching a valuation of $3.92 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.1%. This anticipated growth throughout the forecast period stems from factors such as the authorization of new treatments, the broadening of screening initiatives, the incorporation of AI-powered imaging, heightened patient understanding, and the development of specialized eye care services. Key developments expected during this period involve an increase in the creation of complement inhibitor therapies, a stronger emphasis on prompt detection of retinal conditions, greater financial commitments to innovative ophthalmic medications, the advancement of imaging technologies for monitoring diseases, and a rise in clinical trials focused on AMD treatments.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21984&type=smp

What Drivers Are Influencing The Growth Of The Geographic Atrophy Market?

The growing incidence of age-related macular degeneration (AMD) is anticipated to fuel the expansion of the geographic atrophy market. AMD is an ocular condition that impairs the central retina in older individuals, hindering their ability to discern fine details. The primary driver behind the rising prevalence of AMD is the aging global population, as increased longevity naturally leads to progressive eye damage, making eyes more susceptible to the disease over time. Geographic atrophy treatments offer support to AMD patients by decelerating the advancement of retinal damage and helping to maintain existing vision. For instance, a January 2024 report by Medical News Today, a US-based digital media firm, projects that worldwide age-related macular degeneration cases will climb from 196 million to 288 million by 2040. Consequently, the increasing occurrence of age-related macular degeneration is a significant factor propelling the growth of the geographic atrophy market.

What Segments Are Included Within The Geographic Atrophy Market?

The geographic atrophy market covered in this report is segmented –

1) By Drug Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Complement Inhibitors, Neuroprotective Agents, Other Drug Types

2) By Diagnosis: Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), Multifocal Electroretinography (mfERG)

3) By Route Of Administration: Intravitreal, Oral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Ranibizumab, Aflibercept, Bevacizumab

2) By Complement Inhibitors: Pegcetacoplan, Lfg316

3) By Neuroprotective Agents: Latanoprost, Brimonidine

4) By Other Drug Types: Steroids, Retinoids, Combination Therapy

What Trends Are Reshaping The Dynamics Of The Geographic Atrophy Market?

Leading firms within the geographic atrophy market are concentrating on ground-breaking therapies, including complement inhibitor therapy, to create sophisticated treatments for geographic atrophy. Complement inhibitor therapy serves as a treatment modality designed to decelerate an excessively active immune response associated with specific illnesses, thereby safeguarding healthy cells from harm and diminishing disease advancement. An illustration of this trend is seen in February 2025, when Astellas Pharma Inc., a pharmaceutical entity based in Japan, disclosed the Food and Drug Administration, a US-based government body, approved IZERVAY (avacincaptad pegol intravitreal solution) for geographic atrophy. This regulatory approval permits the use of IZERVAY without restrictions on the dosing duration for addressing geographic atrophy (GA) resulting from age-related macular degeneration (AMD). Such a decision enhances flexibility in the management of GA, presenting extended treatment possibilities for patients and healthcare professionals alike.

Who Are The Core Companies Influencing Trends In The Geographic Atrophy Market?

Major companies operating in the geographic atrophy market are Regeneron Pharmaceuticals Inc, Ocugen Inc, Kodiak Sciences Inc, Apellis Pharmaceuticals Inc, Iveric Bio, Graybug Vision, SparingVision, Alkeus Pharmaceuticals, Kiora Pharmaceuticals, Nanoscope Therapeutics, 4D Molecular Therapeutics, Gensight Biologics, BioMarin Pharmaceutical Inc, Nightstar Therapeutics, MeiraGTx, Retinagenix Inc, Adverum Biotechnologies, AGTC Inc, Editas Therapeutics

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/geographic-atrophy-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Geographic Atrophy Market?

North America was the largest region in the geographic atrophy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the geographic atrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Geographic Atrophy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21984&type=smp

Browse Through More Reports Similar to the Global Geographic Atrophy Market 2026, By The Business Research Company

Athleisure Market Report 2026

https://www.thebusinessresearchcompany.com/report/athleisure-global-market-report

Geographic Information System Market Report 2026

https://www.thebusinessresearchcompany.com/report/geographic-information-system-global-market-report

Geotourism Market Report 2026

https://www.thebusinessresearchcompany.com/report/geotourism-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795